An Open-Label Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL).
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2015
At a glance
- Drugs Bendamustine (Primary) ; Ofatumumab
- Indications B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Cephalon
- 21 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Apr 2011 Planned End Date changed from 1 Apr 2015 to 1 Oct 2011 as reported by ClinicalTrials.gov.
- 05 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.